Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA) (AIR-CF3)

This study has been completed.
Sponsor:
Information provided by:
Gilead Sciences
ClinicalTrials.gov Identifier:
NCT00128492
First received: August 8, 2005
Last updated: May 17, 2011
Last verified: May 2011
  Purpose

The purpose of this study was to evaluate the safety and efficacy of multiple courses of AZLI in patients with cystic fibrosis (CF) and lung infection due to Pseudomonas aeruginosa (PA).


Condition Intervention Phase
Cystic Fibrosis
Drug: AZLI 75 mg two times a day (BID)/ three times a day (TID)
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 3, Open-label, Follow-On Study of Multiple Courses of Aztreonam Lysinate for Inhalation (AI) in Cystic Fibrosis Patients (AIR-CF3)

Resource links provided by NLM:


Further study details as provided by Gilead Sciences:

Primary Outcome Measures:
  • Number of Participants Reporting Adverse Events (AEs) [ Time Frame: Overall study (72 weeks) included nine 28-day courses of study drug alternating with nine 28-day courses off drug ] [ Designated as safety issue: Yes ]

    Participants experiencing at least 1 treatment-emergent AE or at least 1 serious adverse event (SAE) were summarized for the study as a whole. A treatment-emergent AE was any physical or clinical worsening in symptoms or disease experienced by the participant, whether or not the event was considered related to study participation or study procedures. An SAE was any adverse experience that resulted in hospitalization or death.

    Participants were monitored for AEs and SAEs during all on-treatment and off-treatment intervals throughout the 18-month study period.


  • Number of Subjects With <15% or ≥15% Decline in Forced Expiratory Volume in 1 Second [FEV1] From Pretreatment to 30 Minutes After Treatment With AZLI [ Time Frame: Overall study (72 weeks) included nine 28-day courses of study drug alternating with nine 28-day courses off drug ] [ Designated as safety issue: Yes ]
    Airway reactivity (percent change in FEV1 from pretreatment to 30 minutes after treatment with AZLI) was assessed at all study visits in which a participant received AZLI treatment. A participant was included in this endpoint if they experienced a decline in FEV1 of ≥15% at any visit in which they received AZLI.

  • Change in Heart Rate (HR) [ Time Frame: Baseline, and end of treatment Courses 1 (Week 4), 3 (Week 20) and 9 (Week 68) ] [ Designated as safety issue: Yes ]

    HR was recorded at all visits.

    Change from baseline at the end of AZLI treatment Courses 1 (Visit 2), 3 (Visit 4), and 9 (Visit 19) was determined.


  • Change in Systolic and Diastolic Blood Pressure (BP) [ Time Frame: Baseline, and end of treatment Courses 1 (Week 4), 3 (Week 20) and 9 (Week 68) ] [ Designated as safety issue: Yes ]

    BP was recorded at all visits.

    Change from baseline at the end of AZLI treatment Courses 1 (Visit 2), 3 (Visit 4), and 9 (Visit 19) was determined.


  • Change in Temperature [ Time Frame: Baseline, and end of treatment Courses 1 (Week 4), 3 (Week 20) and 9 (Week 68) ] [ Designated as safety issue: Yes ]

    Temperature was recorded at all visits.

    Change from baseline at the end of AZLI treatment Courses 1 (Visit 2), 3 (Visit 4), and 9 (Visit 19) was determined.


  • Change in Respiratory Rate (RR) [ Time Frame: Baseline, and end of treatment Courses 1 (Week 4), 3 (Week 20) and 9 (Week 68) ] [ Designated as safety issue: Yes ]

    RR was recorded at all visits.

    Change from baseline at the end of AZLI treatment Courses 1 (Visit 2), 3 (Visit 4), and 9 (Visit 19) was determined.


  • Serum Hematology - Concentration of White Blood Cells (WBC), Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, and Platelets [ Time Frame: Baseline and end of Course 9 (Week 68) ] [ Designated as safety issue: Yes ]
  • Serum Hematology - Percent of Differential for Basophils, Eosinophils, Lymphocytes, Monocytes, and Neutrophils [ Time Frame: Baseline and end of treatment Course 9 (Week 68) ] [ Designated as safety issue: Yes ]
  • Serum Hematology - Number of Red Blood Cells (RBC) [ Time Frame: Baseline and end of treatment Course 9 (Week 68) ] [ Designated as safety issue: Yes ]
  • Serum Hematology - Hematocrit [ Time Frame: Baseline and end of treatment Course 9 (Week 68) ] [ Designated as safety issue: Yes ]
  • Serum Hematology - Hemoglobin [ Time Frame: Baseline and end of treatment Course 9 (Week 68) ] [ Designated as safety issue: Yes ]
  • Serum Hematology - Mean Corpuscular Volume (MCV) [ Time Frame: Baseline and end of treatment Course 9 (Week 68) ] [ Designated as safety issue: Yes ]
  • Serum Hematology - Mean Corpuscular Hemoglobin (MCH) [ Time Frame: Baseline and end of treatment Course 9 (Week 68) ] [ Designated as safety issue: Yes ]
  • Serum Hematology - Mean Corpuscular Hemoglobin Concentration (MCHC) [ Time Frame: Baseline and end of treatment Course 9 (Week 68) ] [ Designated as safety issue: Yes ]
  • Serum Chemistry - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma-glutamlytransferase (GGT) [ Time Frame: Baseline and end of treatment Course 9 (Week 68) ] [ Designated as safety issue: Yes ]
  • Serum Chemistry - Concentration of Calcium, Creatinine, Direct Bilirubin, Total Bilirubin, Serum Glucose, and Blood Urea Nitrogen [ Time Frame: Baseline and end of treatment Course 9 (Week 68) ] [ Designated as safety issue: Yes ]
  • Serum Chemistry - Concentration of Chloride, Potassium, and Sodium [ Time Frame: Baseline and end of treatment Course 9 (Week 68) ] [ Designated as safety issue: Yes ]
  • Serum Chemistry - Concentration of Total Protein [ Time Frame: Baseline and end of treatment Course 9 (Week 68) ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Change From Baseline in Pseudomonas Aeruginosa (PA) log10 Colony-forming Units (CFU) Per Gram of Sputum [ Time Frame: Baseline, and the end of treatment Courses 1 (Week 4), 3 (Week 20), and 9 (Week 68) ] [ Designated as safety issue: No ]

    Sputum samples were collected at all participant visits of the study for analysis of microbiology endpoints. Sputum samples were processed for qualitative and quantitative culture of PA (each morphotype).

    Due to the skewness of the distribution of CFU data, the data were transformed using the base 10 logarithm, in an attempt to normalize the data and allow for parametric tests, before calculating changes. To account for zero values, 1 was added to each CFU measurement before being transformed. Any CFU data values where PA was not isolated from a valid culture were set to zero.


  • Number of Participants With Other Pathogens [ Time Frame: Baseline; end of treatment Courses 1 (Week 4), 3 (Week 20), and 9 (Week 68); and at Follow-up (Week 72) ] [ Designated as safety issue: Yes ]

    Sputum samples were collected at all study visits for qualitative and quantitative culture for Burkholderia cepacia complex (BCC), Stenotrophomonas maltophilia, Achromobacter xylosoxidans, Staphylococcus aureus (including methicillin-sensitive [MSSA] and methicillin-resistant [MRSA] S.aureus), and fungal organisms.

    Number of participants with other pathogens at baseline and end of AZLI treatment Courses 1, 3, and 9 are reported.


  • Minimum Inhibitory Concentration (MIC) of Aztreonam [ Time Frame: Baseline; end of treatment Courses 1 (Week 4), 3 (Week 20), and 9 (Week 68); and at Follow-up (Week 72) ] [ Designated as safety issue: Yes ]

    The aztreonam susceptibility of PA isolates from expectorated sputum samples (collected at all visits) was assessed.

    MIC50 = minimum inhibitory concentration (minimum concentration of an agent that inhibits 50% of isolates from a particular organism).

    MIC90 = minimum inhibitory concentration (minimum concentration of an agent that inhibits 90% of isolates from a particular organism).

    MIC50 and MIC90 values are single measurements for the entire population and not measured on a per-participant basis.


  • Percent Change in Pulmonary Function (FEV1, FEV1 Percent Predicted, FVC, FEF25-75) [ Time Frame: Baseline, and end of treatment Courses 1 (Week 4), 3 (Week 20), and 9 (Week 68) ] [ Designated as safety issue: No ]

    Spirometry was performed at each visit. FEV1, FVC, and FEF25-75 were recorded at all visits according to American Thoracic Society (ATS) guidelines.

    FEV1 = the volume of air exhaled in 1 second. FEV1 % predicted is a normalized value of FEV1 calculated using the Knudson equation, based upon participant age, gender, and height. FVC = (forced vital capacity) the maximal volume of air exhaled with maximally forced effort from a position of maximal inspiration. FEF25-75 = forced expiratory flow from 25% to 75% of the FVC.

    The percent change from baseline is presented for each endpoint.


  • Change in Clinical Symptoms as Assessed by the Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Scale (CFQ-R RSS) [ Time Frame: Baseline, and end of treatment Courses 1 (Week 4), 3 (Week 20), and 9 (Week 68) ] [ Designated as safety issue: No ]
    The CFQ-R was administered at baseline and every visit thereafter. The endpoint was change in respiratory symptoms from baseline, assessed with the CFQ-R RSS (range of scores: 0-100; higher scores indicate fewer symptoms). The minimal clinically important difference (MCID) corresponds to the smallest change in symptoms that a patient can detect and is a change in score of 4 points.

  • Time to First Hospitalization Due to a Respiratory Event [ Time Frame: Overall study (72 weeks) included nine 28-day courses of study drug alternating with nine 28-day courses off drug ] [ Designated as safety issue: No ]

    Details of all hospitalizations, including the dates of admission and discharge, were recorded on the serious adverse event (SAE) electronic case report form (eCRF).

    Time to first hospitalization was the number of days from baseline (Visit 1) to the date of first hospitalization or the date of study completion (last visit) /or early withdrawal if censored.


  • Change in Body Weight [ Time Frame: Baseline, and end of treatment Courses 1 (Week 4), 3 (Week 20), and 9 (Week 68) ] [ Designated as safety issue: No ]
    Weight was measured at all visits and was reported to the nearest 0.1 kg/lb. Percent change in weight from baseline was calculated.

  • Missed School/Work Days Due to CF Symptoms [ Time Frame: Overall study (72 weeks) included nine 28-day courses of study drug alternating with nine 28-day courses off drug ] [ Designated as safety issue: No ]

    Participants were provided with a diary card at each visit to record days of work and/or school missed due to their CF symptoms.

    The percentage of school/work days missed was calculated as the total number of school/work days missed divided by the total number of on-study days multiplied by 100 across all participants in a treatment group.


  • Time to Intravenous (IV) Antipseudomonal Antibiotics [ Time Frame: Overall study (72 weeks) included nine 28-day courses of study drug alternating with nine 28-day courses off drug ] [ Designated as safety issue: No ]
    Use of IV antipseudomonal antibiotics was compiled from data recorded on the Concomitant Medications eCRF. The time to first IV antipseudomonal antibiotic use was the number of days from baseline (Visit 1) to the date of first IV antipseudomonal antibiotic use or the date of study completion (last visit) /or early withdrawal if censored.


Enrollment: 274
Study Start Date: August 2005
Study Completion Date: January 2009
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Detailed Description:

People with CF often have lung infections that occur repeatedly or worsen over time. The lung infections are often caused by PA. Treatment with antibiotics is used to reduce the presence of the bacteria. The antibiotics may be given orally, intravenously, or inhaled as a mist. The purpose of this study was to evaluate whether AZLI, an investigational formulation of the antibiotic aztreonam, is safe in repeated courses in patients with CF and PA.

A course of AZLI treatment in this study comprised 28 days, followed by a 28-day period off treatment. Participants could receive up to 9 courses of AZLI, with a total time on study of up to 18 months. Safety and efficacy results for the 18-month, 9-course period are reported, with efficacy results presented on a by-treatment course basis.

  Eligibility

Ages Eligible for Study:   6 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Compliance with Studies CP-AI-005 (NCT00104520) or CP-AI-007 (NCT00112359) by taking at least 50% of expected study medication.
  • Completion of CP-AI-005 or CP-AI-007 or was withdrawn due to need for antipseudomonal antibiotics or for an AE unrelated to study medication tolerance.
  • Ability to provide written informed consent/assent prior to initiation of study-related procedures.
  • Ability to perform reproducible pulmonary function tests.

Exclusion Criteria:

  • Use of any investigational medication or device between the last visit of CP-AI-005 or CP-AI-007 and Visit 1 of this study.
  • Concurrent participation in a study of another investigational drug or device.
  • Current use of oral corticosteroids in doses exceeding the equivalent of 10 mg prednisone/day or 20 mg prednisone every other day.
  • History of sputum or throat swab culture yielding Burkholderia cepacia in the previous 2 years.
  • History of daily continuous oxygen supplementation or requirement for more than 2 liters/minute at night.
  • Inability to tolerate study medication in CP-AI-005 or CP-AI-007.
  • Known local or systemic hypersensitivity to aztreonam.
  • Inability to tolerate inhalation of a short acting beta-2 agonist.
  • Abnormal renal or hepatic function based on results of most recent test.
  • Female of child-bearing potential who was pregnant, lactating, or not (in the opinion of the investigator) practicing an acceptable method of birth control.
  • Any serious or active medical or psychiatric illness which, in the opinion of the investigator, would have interfered with participant treatment, assessment, or compliance with the protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00128492

  Hide Study Locations
Locations
United States, Alabama
Birmingham, Alabama, United States
United States, Alaska
Anchorage, Alaska, United States
United States, Arizona
Phoenix, Arizona, United States
United States, Arkansas
Little Rock, Arkansas, United States
United States, California
La Jolla, California, United States
Los Angeles, California, United States
Oakland, California, United States
Orange, California, United States
United States, Colorado
Denver, Colorado, United States
United States, Connecticut
Hartford, Connecticut, United States
New Haven, Connecticut, United States
United States, Florida
Jacksonville, Florida, United States
Orlando, Florida, United States
United States, Georgia
Atlanta, Georgia, United States
Augusta, Georgia, United States
United States, Illinois
Chicago, Illinois, United States
Glenview, Illinois, United States
Maywood, Illinois, United States
Park Ridge, Illinois, United States
United States, Indiana
Indianapolis, Indiana, United States
United States, Kansas
Wichita, Kansas, United States
United States, Louisiana
Shreveport, Louisiana, United States
United States, Massachusetts
Boston, Massachusetts, United States
United States, Michigan
Ann Arbor, Michigan, United States
Detroit, Michigan, United States
United States, Minnesota
Minneapolis, Minnesota, United States
United States, Missouri
Columbia, Missouri, United States
St. Louis, Missouri, United States
United States, Nevada
Las Vegas, Nevada, United States
United States, New Jersey
Livingston, New Jersey, United States
Morristown, New Jersey, United States
United States, New York
Albany, New York, United States
Brooklyn, New York, United States
Buffalo, New York, United States
New Hyde Park, New York, United States
New York, New York, United States
Syracuse, New York, United States
Valhalla, New York, United States
United States, North Carolina
Chapel Hill, North Carolina, United States
United States, Ohio
Akron, Ohio, United States
Cincinnati, Ohio, United States
Columbus, Ohio, United States
Dayton, Ohio, United States
United States, Oklahoma
Oklahoma City, Oklahoma, United States
United States, Pennsylvania
Hershey, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
United States, South Carolina
Charleston, South Carolina, United States
Columbia, South Carolina, United States
United States, Texas
Houston, Texas, United States
San Antonio, Texas, United States
United States, Utah
Salt Lake City, Utah, United States
United States, Virginia
Portsmouth, Virginia, United States
Richmond, Virginia, United States
United States, Washington
Seattle, Washington, United States
United States, West Virginia
Morgantown, West Virginia, United States
Australia, New South Wales
Westmead, New South Wales, Australia
Australia, Queensland
Herston, Queensland, Australia
Australia, South Australia
Adelaide, South Australia, Australia
Australia, Victoria
Prahan, Victoria, Australia
Australia, Western Australia
Nedlands, Western Australia, Australia
Perth, Western Australia, Australia
Canada, Alberta
Edmonton, Alberta, Canada
Canada, Ontario
London, Ontario, Canada
New Zealand
Auckland, New Zealand
Sponsors and Collaborators
Gilead Sciences
Investigators
Study Director: Bruce Montgomery, MD Gilead Sciences
  More Information

No publications provided

Responsible Party: Mark Bresnik, MD, Director, Clinical Research, Gilead Sciences, Inc.
ClinicalTrials.gov Identifier: NCT00128492     History of Changes
Other Study ID Numbers: CP-AI-006
Study First Received: August 8, 2005
Results First Received: June 3, 2010
Last Updated: May 17, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Gilead Sciences:
cystic fibrosis
Pseudomonas aeruginosa

Additional relevant MeSH terms:
Cystic Fibrosis
Fibrosis
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Pathologic Processes
Aztreonam
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 28, 2014